(Total Views: 191)
Posted On: 02/02/2017 12:13:57 PM
Post# of 72446
Re: NotRichYet2 #31074
Aprea's APR-246 reactivates mutant p53, but not wild type.
https://www.aprea.com/our-science/the-aprea-t...-approach/
Their P2 ovarian cancer trial started last October so they are a little ahead of K.
https://www.aprea.com/news/aprea-therapeutics...an-cancer/
K reactivates wild type p53. It'll be great if both drugs work so patients can choose depending on their p53 status.
https://www.aprea.com/our-science/the-aprea-t...-approach/
Their P2 ovarian cancer trial started last October so they are a little ahead of K.
https://www.aprea.com/news/aprea-therapeutics...an-cancer/
K reactivates wild type p53. It'll be great if both drugs work so patients can choose depending on their p53 status.
Quote:
Is CTIX the only Bio-tech company with trials currently specifically targeting p53 in some fashion ???
(2)
(0)
